Measuring how acyclovir moves in children with cancer
Part of Cancer, Infections clinical trials.
This study checks how acyclovir behaves in the body when it’s given by mouth or through an IV to children receiving cancer care. It may help doctors better choose doses and monitor the medicine in kids who need prevention or treatment of certain viral infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has blood cancer (a hematologic malignancy), or is getting a stem-cell transplant (HSCT), or is on very strong cancer chemotherapy
- Your child needs acyclovir (ACV) to prevent or treat herpes or shingles viruses
- ACV must be taken either through an IV or by mouth
- The study site must be able to do therapeutic drug monitoring (regular blood tests to check ACV levels)
- A parent or legal guardian must be able to sign the consent form for your child
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how to adjust acyclovir dosing based on body weight and kidney function. It includes healthy volunteers across normal weight, overweight, and obesity levels to better understand how the drug moves through the body.
This trial tests whether giving the antiviral drug acyclovir early can help people on ventilators who show signs of herpes virus in the throat. The goal is to reduce complications and improve recovery.
This trial tests whether acyclovir, an antiviral drug, can help patients with pneumonia who are on breathing support and have herpes simplex virus in their lung fluid. The goal is to see if it improves recovery.
This study tests whether a personalized dose of the antiviral drug ganciclovir can better treat CMV infection in children with weakened immune systems. It aims to make the treatment more effective and safer for each child.
This study tests whether taking an antiviral medicine (aciclovir) by mouth can help people recover from meningitis caused by the herpes simplex virus type 2 (HSV-2). You would receive either the active medicine or a placebo (a pill with no active ingredient) to see if it improves recovery.
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
Hear when a new Transplantation Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.